Link to Full Article Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high […]
Link to Full Article Founder, CEO John Parker Taking on New Role as Chief Scientific Officer, Remaining on Board Artarmon, Australia – February 12, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann […]
Link to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]
Link to Full Article Artarmon, Australia – December 22, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) announced today that the UK’s National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled “Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain.” The MIB states Evoke would be used as a […]
Link to Full Article Strengthens corporate leadership as company moves toward global commercialization Artarmon, Australia – June 9, 2020 – Saluda Medical Pty Limited (“Saluda Medical”), a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with debilitating neurological disorders, today announced the key leadership appointments of Jim Schuermann as President and Robert Gaffney as Chief Operating […]
Link to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]
Link to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]
Link to Full Article Regulatory approval is the next major hurdle facing Saluda Medical, the biotech company which is led Cochlear’s former chief technology officer and was responsible for the biggest domestic life sciences capital raising of the last fiscal year. Saluda Medical said in June it had raised $US75 million ($106 million) from […]
Artarmon, NSW, Australia – June 28, 2019 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that it has secured $75 million in equity financing from Boston Scientific Corporation (NYSE: BSX) and Redmile Group LLC to fund the final stages of development through commercialization of its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for […]
Proceeds to fund continued development of Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System Evoke Trial Validates Level I Evidence Achieved Through First Double-Blind Randomized U.S. Pivotal Study in SCS Proceeds to fund continued development of Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System Evoke Trial Validates Level I Evidence Achieved Through First Double-Blind Randomized U.S. […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: